ArticleDermatology and therapy2026

Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib.

Ho Eun Gwag et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.